<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Netherton syndrome</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Netherton syndrome</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Netherton syndrome</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jonathan A Dyer, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Moise L Levy, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jennifer L Hand, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Rosamaria Corona, MD, DSc</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 30, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H3320601962"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Netherton syndrome ([NS] Comel-Netherton; MIM #256500) is a rare autosomal recessive disorder of cornification caused by mutations in the serine protease inhibitor of Kazal type 5 gene (<em>SPINK5</em>), which encodes a serine protease inhibitor expressed in epithelial and mucosal surfaces. NS is clinically characterized by the classic triad of congenital ichthyosiform erythroderma, a specific hair shaft abnormality termed trichorrhexis invaginata ("bamboo hair"), and an atopic diathesis [<a href="#rid1">1</a>].</p><p>NS is one of the most severe disorders of cornification. Infants typically present at birth with a generalized scaling erythroderma and have a high risk of life-threatening complications, such as hypernatremic dehydration, failure to thrive, and sepsis. In older children, a wide range of allergic manifestations may occur, including severe atopic dermatitis, asthma, hay fever, and markedly elevated serum levels of immunoglobulin E.</p><p>This topic will review the pathogenesis, clinical manifestations, diagnosis, and management of NS. Other disorders of cornification and disorders characterized by peeling skin are discussed separately. Other causes of neonatal and infantile erythroderma are also discussed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/15465.html" rel="external">"Overview and classification of the inherited ichthyoses"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/15512.html" rel="external">"Peeling skin syndromes"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/89273.html" rel="external">"Erythroderma in children"</a>.)</p><p></p><p class="headingAnchor" id="H3876411530"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>The precise incidence of NS is unknown but is estimated at 1:100,000 to 1:200,000 live births [<a href="#rid2">2</a>]. NS is estimated to account for approximately 20 percent of neonatal erythroderma cases [<a href="#rid3">3</a>].</p><p class="headingAnchor" id="H2066686047"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>NS is caused by autosomal recessive mutations in the serine protease inhibitor of Kazal type 5 gene (<em>SPINK5</em>; OMIM 605010) on chromosome 5q32 [<a href="#rid4">4</a>]. More than 70 distinct <em>SPINK5</em> mutations specific to an individual or family have been reported.</p><p><em>SPINK5</em> encodes a multidomain serine protein kinase known as lymphoepithelial Kazal type inhibitor (LEKTI). Most mutations, whether small base deletions/insertions, nonsense, or splice site mutations, lead to premature stop codons and protein truncation, resulting in defective expression of LEKTI.</p><p>LEKTI functions as a "super" serine protease inhibitor [<a href="#rid5">5</a>]. Among the proteases it directly inhibits are several kallikreins, especially kallikrein 5 (KLK5). Kallikreins are critical epidermal proteases, important for regulating skin desquamation, inflammation, and maintaining skin barrier integrity. Importantly, the constitutive overactivity of kallikrein 5 (KLK5) and its related peptidases is present in utero; thus, at birth, the epidermal barrier is greatly impaired and there is dramatic upregulation of inflammatory signaling molecules. Specific <em>SPINK5</em> polymorphisms, especially 420Lys (420K), have been associated with atopic dermatitis and atopy [<a href="#rid6">6-8</a>].</p><p>LEKTI activity is influenced by local pH; the neutral pH of the deeper aspects of the epidermis stimulates its activity, while the gradient to a more acidic pH in the outer layers of the epidermis impairs its activity, allowing KLK5 (among others) to become active, leading to protein degradation and desquamation of the outer epidermal layers in an organized, regulated fashion. In NS, LEKTI deficiency results in KLK5 activation in all levels of the epidermis, leading to premature degradation of the corneodesmosomal components of the epidermal barrier. This profoundly and continuously degraded epidermal barrier leads to chronic inflammation, superficial desquamation (ichthyosiform erythroderma), and the KLK5-mediated activation of protease-activated receptor-2, which leads to production of a variety of proinflammatory cytokines including thymic stromal lymphopoietin (TSLP), a cytokine strongly upregulated in atopic dermatitis [<a href="#rid9">9</a>].</p><p>TSLP activates Langerhans cells, which induce T cell differentiation into Th2 cells after migration to draining regional lymph nodes. Additional cytokines upregulated in the setting of LEKTI deficiency include macrophage-derived cytokine, tumor necrosis factor (TNF)-alpha, interleukin (IL) 8, and thymus- and activation-regulated cytokine. In the setting of LEKTI deficiency, these overly activated pathways are constitutive and unremitting. Further emphasizing the importance of KLK5 in the pathogenesis of NS are the findings that KLK5-deficient, LEKTI-deficient mice exhibit a normalized phenotype without the majority of cutaneous and clinical findings present when KLK5 is functional [<a href="#rid10">10</a>]. LEKTI is also expressed in the thymus, the importance of which is unknown.</p><p>The constitutive protease activity in NS skin leads not only to degradation of the stratum corneum cell adhesion but also to degradation of secreted lamellar body (LB) protein contents, including two ceramide-generating enzymes (acidic sphingomyelinase and beta-glucocerebrosidase), resulting in a profound barrier defect, which contributes to increased risk of infection. Studies have shown that antimicrobial proteins such as the cathelicidin LL-37, which typically are present in normal skin, are reduced in NS. LL-37 is typically loaded in LB to be secreted during cornification of the epidermis. Although LL-37 loading into LB is normal in NS and LB secretion is accelerated, the levels of LL-37 rapidly become undetectable after LB secretion, likely due to degradation by the high levels of active epidermal proteases [<a href="#rid11">11</a>].</p><p>In a study of the immune profiles of a variety of ichthyosis subtypes, patients with NS were found to exhibit some upregulation of TNF-alpha as well as significant upregulation of T helper type 17 (Th17)/IL-23 pathway genes very similar to psoriasis [<a href="#rid12">12</a>]. NS patients had the highest induction of Th17 pathway genes amongst the ichthyosis subgroups tested, with striking upregulation of IL-19, which leads to amplification of IL-17 effects on keratinocytes.</p><p class="headingAnchor" id="H269521972"><span class="h1">CLINICAL MANIFESTATIONS</span><span class="headingEndMark"> — </span>NS is characterized by the classic triad of congenital ichthyosiform erythroderma, a specific hair shaft abnormality termed trichorrhexis invaginata, and allergic manifestations with elevated serum levels of immunoglobulin. However, the phenotype of NS may be quite variable among patients and even within families.</p><p>Some patients may present with a milder phenotype, possibly associated with residual expression of lymphoepithelial Kazal type inhibitor (LEKTI) [<a href="#rid13">13</a>]. In other patients, one or more of the classic features may not be present, and changes in phenotype severity may occur over time [<a href="#rid5">5</a>]. Of note, the original patient described by Netherton had significant improvement in her skin and hair findings as she aged [<a href="#rid1">1</a>].</p><p>Clear genotype-phenotype correlations have not been identified, although in a small number of Japanese patients a link has been found between LEKTI domain deficiency and clinical manifestations [<a href="#rid14">14</a>]. There are also reports of mutations associated with early lethality or very severe manifestations of the disease [<a href="#rid15">15-17</a>].</p><p class="headingAnchor" id="H2842798364"><span class="h2">Neonatal findings</span><span class="headingEndMark"> — </span>Neonates with NS are often premature and may exhibit diffuse ichthyosiform erythroderma at birth  (<a class="graphic graphic_picture graphicRef109528" href="/z/d/graphic/109528.html" rel="external">picture 1</a>). There are reports of NS infants being born with a collodion membrane, although this is not common, if it occurs at all. Hair is usually sparse and grows slowly. Congenital alopecia may be noted.</p><p>Newborns with NS are quite labile in the first few weeks of life. They have a high risk of life-threatening complications, including hypernatremic dehydration and hypothermia due to extensive transepidermal water loss. The risk of infection and sepsis is also elevated. Other complications include severe failure to thrive and enteropathy with villous atrophy. (See  <a class="medical medical_review" href="/z/d/html/89273.html" rel="external">"Erythroderma in children"</a>.)</p><p>Additionally, as the epidermal barrier is substantially impaired, the risk of transcutaneous absorption is extremely high in these infants. Topical medications should be avoided or used with great caution.</p><p class="headingAnchor" id="H1839034577"><span class="h2">Cutaneous manifestations</span><span class="headingEndMark"> — </span>Beyond the neonatal period, the cutaneous findings of NS are variable and tend to improve over time. However, in some patients, a generalized scaling erythroderma may be persistent and at times severe enough to be mistaken for other forms of ichthyosis, such as autosomal recessive congenital ichthyosis.</p><p>Most patients evolve with age to a milder cutaneous phenotype, with erythematous patches and scaling mimicking an eczematous eruption such as atopic dermatitis. The erythema may be symmetrical and exhibit patterned shapes. Pustular lesions, which can mimic pustular psoriasis, have also been described [<a href="#rid18">18,19</a>].</p><p>Eventually, many patients will manifest ichthyosis linearis circumflexa (ILC), which is the distinctive cutaneous feature of NS. ILC usually appears after two years of age and is characterized by migratory serpiginous erythematous plaques with peripheral double-edged scaling  (<a class="graphic graphic_picture graphicRef87482" href="/z/d/graphic/87482.html" rel="external">picture 2</a>). ILC is variable in severity and extent and waxes and wanes with time. In some patients with proven serine protease inhibitor of Kazal type 5 (<em>SPINK5</em>) gene mutations, ILC is the only clinical manifestation of NS [<a href="#rid20">20</a>].</p><p>In adulthood, some NS patients develop striking hypertrophic papillomas in the flexures, most commonly in the inguinal folds, gluteal cleft, and groin [<a href="#rid5">5</a>]. Human papillomavirus DNA, including DNA of epidermodysplasia verruciformis-associated beta-papillomavirus, has been detected in some of these lesions [<a href="#rid21">21</a>]. Buschke-Lowenstein tumors requiring surgical intervention have been reported in a few cases [<a href="#rid22">22,23</a>].</p><p>There are a few isolated reports of skin malignancies, including multiple basal cell carcinomas and squamous cell carcinomas, occurring at an early age in patients with NS [<a href="#rid24">24,25</a>]. The overall incidence of this phenomenon is not known.</p><p class="headingAnchor" id="H1236121910"><span class="h2">Hair abnormalities</span><span class="headingEndMark"> — </span>In many NS patients, the hair is typically lusterless, dry, short, and hard to style or manage  (<a class="graphic graphic_picture graphicRef109572" href="/z/d/graphic/109572.html" rel="external">picture 3</a>). Some patients with longer hairs may have visible nodes along the hair shafts.</p><p>The pathognomonic finding of trichorrhexis invaginata (TI) of hair and eyebrows ("bamboo hair" or "ball and socket deformity") may be often detected on trichogram or trichoscopy by one year of age. However, in some patients with genotyped <em>SPINK5</em> mutations, TI may be absent [<a href="#rid26">26</a>]. (See <a class="local">'Hair examination'</a> below.)</p><p>Other hair shaft defects that may occur in NS include trichorrhexis nodosa (TN) and pili torti. TN is characterized by nodes along the hair shaft that result from separation and fraying of cortical fibers due to disruption of the overlying cuticular cells. Affected hairs may fracture through these weak points in the hair shaft, which appear like two brooms or brushes thrust together end to end.</p><p class="headingAnchor" id="H1407640831"><span class="h2">Atopic manifestations</span><span class="headingEndMark"> — </span>Most patients with NS have elevated immunoglobulin E (IgE) levels and eosinophilia [<a href="#rid27">27</a>]. Manifestations of atopy may become apparent in the neonatal period and increase during childhood. They include atopic dermatitis, which can be severe; food allergies, which are often severe and multiple; hay fever; and asthma. Angioedema and anaphylaxis, especially to foods, have also been reported. The levels of specific IgE to multiple allergens typically increase with age [<a href="#rid27">27</a>].</p><p class="headingAnchor" id="H3893669320"><span class="h2">Extracutaneous manifestations</span><span class="headingEndMark"> — </span>Children with NS may show a mild developmental delay, short stature and growth hormone deficiency [<a href="#rid28">28</a>], intellectual disability, recurrent cutaneous and systemic infections, and pancreatic insufficiency [<a href="#rid29">29</a>].</p><p class="headingAnchor" id="H4210898210"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The diagnosis of NS may be difficult, due to the variability of the clinical presentation and its change over time. A high index of suspicion is required for patients manifesting a mild or incomplete phenotype.</p><p class="headingAnchor" id="H3013019253"><span class="h2">Clinical suspicion</span><span class="headingEndMark"> — </span>NS should be suspected in all neonates and infants presenting with ichthyosiform erythroderma, as approximately 20 percent will have NS [<a href="#rid2">2</a>].</p><p>In older children, the presence of serpiginous erythematous plaques with typical double-edged scale (ichthyosis linearis circumflexa, [ILC]) on the trunk and extremities  (<a class="graphic graphic_picture graphicRef87482" href="/z/d/graphic/87482.html" rel="external">picture 2</a>) suggests NS. This diagnosis should also be considered in children with recalcitrant atopic eczema that does not respond to standard treatment  (<a class="graphic graphic_table graphicRef50324" href="/z/d/graphic/50324.html" rel="external">table 1</a>).</p><p>In both children and adults, the presence of sparse and fragile hair in association with eczematous lesions resembling atopic dermatitis should raise suspicion of NS and prompt careful microscopic or dermoscopic examination of hairs and eyebrows for trichorrhexis invaginata (TI). (See <a class="local">'Hair examination'</a> below.)</p><p class="headingAnchor" id="H1273671674"><span class="h2">Skin biopsy</span><span class="headingEndMark"> — </span>Routine histopathologic examination is generally not helpful for the diagnosis of NS. However, it can be helpful to differentiate NS from other disorders that present with similar clinical manifestations. Immunostaining for lymphoepithelial Kazal type inhibitor (LEKTI) may support the diagnosis.</p><p class="headingAnchor" id="H2850435534"><span class="h3">Histopathologic findings</span><span class="headingEndMark"> — </span>Skin biopsies of NS typically exhibit psoriasiform hyperplasia, with skin inflammation, thinning, and a diminished granular layer. Additional findings include sub/intracorneal splitting, clear cells in the upper epidermis/stratum corneum, dyskeratosis, a dermal inflammatory infiltrate including neutrophils and/or eosinophils, and vascular dilatation [<a href="#rid30">30</a>]. Electron microscopy of NS exhibits findings associated with abnormal differentiation and accelerated desquamation including granular layer diminution, retained nuclei in the stratum corneum, and premature lamellar body (LB) secretion [<a href="#rid5">5</a>].</p><p class="headingAnchor" id="H1506324574"><span class="h3">LEKTI immunostaining</span><span class="headingEndMark"> — </span>Many NS patients exhibit absent LEKTI staining in the epidermis. Some patients with "leaky" mutations allowing slight residual LEKTI expression will exhibit diminution of LEKTI. In contrast, a patchy LEKTI staining may be occasionally seen in patients with atopic dermatitis or psoriasis but not in NS [<a href="#rid30">30</a>].</p><p class="headingAnchor" id="H2265879658"><span class="h2">Hair examination</span><span class="headingEndMark"> — </span>In a patient suspected to have NS, the examination of the hair and eyebrows under a microscope (trichogram) or a dermatoscope (trichoscopy) can confirm the presence of TI [<a href="#rid31">31,32</a>]. In TI, the distal part of the hair shaft collapses into the proximal aspect of the shaft due to a defect in keratinization of the internal root sheath, creating the bamboo-like node which gives the defect its name  (<a class="graphic graphic_picture graphicRef109572" href="/z/d/graphic/109572.html" rel="external">picture 3</a>). Due to this structural weakness, the hairs break easily, leaving behind a cup-shaped end to the fractured hair (the so-called "golf-tee" hairs) [<a href="#rid2">2,33</a>].</p><p>Because in most cases only a small percentage of hairs are affected, the appropriate evaluation of hair in these patients should involve the sampling of numerous hairs from various areas of the scalp. Often hundreds of hairs must be examined to find an example of TI [<a href="#rid34">34</a>]. The presence of TI even in a single hair, in association with typical skin findings, is considered sufficient to make the diagnosis of NS. Trichoscopy may aid in this by allowing examination of hairs in vivo on the patient.</p><p>Prior to harvesting, the hairs can be rubbed between the fingers to accentuate any underlying defects. In difficult cases, the eyebrows should be examined, as they can exhibit a higher frequency of hair shaft abnormalities [<a href="#rid35">35</a>].</p><p>So-called "matchstick" hairs have been described in the eyebrows of some NS patients. Characterized by short hair shafts with a bulging tip similar to an unstruck match, these hairs are likely equivalent to "golf-tee" scalp hairs and represent hair shafts that have fractured through an area of TI [<a href="#rid36">36</a>].</p><p class="headingAnchor" id="H2836562932"><span class="h2">Genetic testing</span><span class="headingEndMark"> — </span>Due to the increasing availability of rapid exome sequencing and mutation analysis, genetic testing for serine protease inhibitor of Kazal type 5 (<em>SPINK5</em>) gene mutations has become the initial test in patients suspected to have NS [<a href="#rid30">30</a>]. Genetic testing will identify a germline <em>SPINK5</em> mutation and confirm the diagnosis in approximately 66 to 75 percent of cases [<a href="#rid37">37</a>].</p><p>Mutational analysis is available from several laboratories in the United States and other countries.</p><p class="headingAnchor" id="H1680233296"><span class="h2">Diagnostic criteria</span><span class="headingEndMark"> — </span>The diagnosis of NS is made based upon the presence of one or more of the following criteria in addition to allergic disease (ie, atopic dermatitis, atopic diathesis, food allergies, hay fever, history of anaphylaxis, elevated IgE levels, eosinophilia):</p><p class="bulletIndent1"><span class="glyph">●</span>Typical skin lesions – Scaling erythroderma, ILC</p><p class="bulletIndent1"><span class="glyph">●</span>Typical hair findings – TI, "golf-tee" and "matchstick" hairs</p><p class="bulletIndent1"><span class="glyph">●</span>History of NS in a sibling</p><p class="bulletIndent1"><span class="glyph">●</span>Identification of a germline <em>SPINK5</em> mutation by DNA sequencing</p><p></p><p>Genetic testing will identify a germline <em>SPINK5</em> mutation and confirm the diagnosis in approximately 66 to 75 percent of cases; in some patients, the diagnosis of NS relies upon clinical suspicion and findings.</p><p class="headingAnchor" id="H3983248614"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>In neonates, the cutaneous manifestations of NS may closely resemble other infantile erythrodermas, particularly nonbullous congenital ichthyosiform erythroderma (CIE) and erythrodermic psoriasis. Atopic dermatitis, lamellar ichthyosis, primary immunodeficiency syndromes, seborrheic dermatitis, and acrodermatitis enteropathica should also be excluded (see  <a class="medical medical_review" href="/z/d/html/89273.html" rel="external">"Erythroderma in children"</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Autosomal recessive congenital ichthyosis</strong> – Infants with autosomal recessive congenital ichthyosis (ARCI), including lamellar ichthyosis (LI) and nonbullous CIE, exhibit diffuse scaling erythroderma at birth and during early childhood as NS children. However, newborns with ARCI are often born with a collodion membrane  (<a class="graphic graphic_picture graphicRef62827" href="/z/d/graphic/62827.html" rel="external">picture 4</a>), which is replaced in the first few weeks of life by thick plate-like scale with variable erythroderma in infants with LI  (<a class="graphic graphic_picture graphicRef109632" href="/z/d/graphic/109632.html" rel="external">picture 5</a>) and by small white scales and prominent erythroderma in CIE  (<a class="graphic graphic_picture graphicRef109634" href="/z/d/graphic/109634.html" rel="external">picture 6</a>). In addition, trichorrhexis invaginata (TI) and atopic manifestations are not characteristic of ARCI. (See  <a class="medical medical_review" href="/z/d/html/15465.html" rel="external">"Overview and classification of the inherited ichthyoses", section on 'Lamellar ichthyosis and congenital ichthyosiform erythroderma'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Erythrodermic psoriasis/pustular psoriasis</strong> – There are multiple reports of infants with diffuse pustular erythematous skin eruptions mimicking pustular or erythrodermic psoriasis who were later diagnosed with NS [<a href="#rid18">18,19</a>]. However, the absence of hair abnormalities, atopy, or allergy support the diagnosis of psoriasis. (See  <a class="medical medical_review" href="/z/d/html/89271.html" rel="external">"Pustular psoriasis: Pathogenesis, clinical manifestations, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Atopic dermatitis</strong> – Atopic dermatitis is not associated with the hair shaft abnormalities seen in NS, nor with ichthyosis linearis circumflexa (ILC). In addition, atopic manifestations are much more severe in NS than in atopic dermatitis. (See  <a class="medical medical_review" href="/z/d/html/1729.html" rel="external">"Atopic dermatitis (eczema): Pathogenesis, clinical manifestations, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acrodermatitis enteropathica</strong> – Acrodermatitis enteropathica is a recessively inherited partial defect of intestinal zinc absorption. Affected infants develop an erythematous and vesiculobullous dermatitis  (<a class="graphic graphic_picture graphicRef71329" href="/z/d/graphic/71329.html" rel="external">picture 7</a>), diarrhea, and severe growth retardation. Although hair abnormalities (alopecia) may occur in acrodermatitis enteropathica, the specific TI hair shaft defect is not seen. The incidence of allergic disease is also not increased. (See  <a class="medical medical_review" href="/z/d/html/5354.html" rel="external">"Zinc deficiency and supplementation in children", section on 'Acrodermatitis enteropathica'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Primary immunodeficiency syndromes</strong> – Some forms of primary immunodeficiency, including Omenn syndrome and hyperimmunoglobulin E syndrome  (<a class="graphic graphic_picture graphicRef61049" href="/z/d/graphic/61049.html" rel="external">picture 8</a>), may present with diffuse atopic dermatitis-like eruption, or scaly, ichthyosiform erythroderma, and increased risk of infection. However, in contrast with NS, TI is absent and the incidence of allergic disease is not increased. The incidence and types of infections also differ from NS. Trichogram, skin biopsy, or genetic analysis can differentiate difficult cases. (See  <a class="medical medical_review" href="/z/d/html/3955.html" rel="external">"Severe combined immunodeficiency (SCID): An overview"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Seborrheic dermatitis</strong> – Diffuse seborrheic dermatitis can present with erythroderma, although the scaling is typically greasier and not as dry as that seen in NS or other disorders of cornification. Seborrheic dermatitis typically exhibits a scalp/flexural predominance. Additionally, TI and severe allergic disease are not characteristic of seborrheic dermatitis. (See  <a class="medical medical_review" href="/z/d/html/16261.html" rel="external">"Cradle cap and seborrheic dermatitis in infants"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Peeling skin syndrome type B </strong>– Inflammatory peeling skin syndrome (peeling skin syndrome type B) is an autosomal recessive disorder caused by loss-of-function mutations in the corneodesmosin gene and shares striking clinical similarities with NS, including ichthyosiform erythroderma at birth, superficial skin peeling, failure to thrive, food allergies, asthma, urticaria, angioedema, and recurrent skin infections [<a href="#rid34">34,38,39</a>]. A deficiency of corneodesmosin, a protein involved in maintaining cell adhesion in the stratum corneum, either due to genetic mutations (as in the peeling skin syndrome type B) or to excess proteolysis from lymphoepithelial Kazal type inhibitor (LEKTI) deficiency (as in NS), results in aberrant regulation of epidermal desquamation, barrier impairment, skin inflammation, and increased immunoglobulin E levels [<a href="#rid40">40</a>]. (See  <a class="medical medical_review" href="/z/d/html/15512.html" rel="external">"Peeling skin syndromes", section on 'Generalized inflammatory (type B) peeling skin syndrome'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Severe dermatitis, multiple allergies, and metabolic wasting (SAM) syndrome</strong> – Severe dermatitis, multiple allergies, and metabolic wasting (SAM) syndrome is a newly described autosomal recessive genodermatosis caused by homozygous mutations in the desmoglein-1 gene. SAM syndrome shows significant clinical overlap with NS, including congenital erythroderma, scaling, skin erosions, and poor hair growth, but not TI, increased IgE levels, and severe food allergies [<a href="#rid40">40</a>]. Failure to thrive and recurrent skin and respiratory infections are also common. Skin histopathology reveals acantholysis with subcorneal and intragranular cellular separation. (See  <a class="medical medical_review" href="/z/d/html/15512.html" rel="external">"Peeling skin syndromes", section on 'SAM syndrome'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Exfoliative ichthyosis</strong> – Autosomal recessive exfoliative ichthyosis (AREI) is a rare ichthyosis caused by mutations in cystatin A, also known as cysteine protease inhibitor A [<a href="#rid41">41</a>]. It is characterized by congenital erythroderma, hyperhidrosis, and diffuse fine skin scaling. Peeling of the palms and soles beginning in childhood and worsened by immersion in water or occlusion occurs. In contrast with NS, AREI is not associated with a severe alteration of the skin barrier function, atopy, and hair abnormalities. The presence of palmoplantar hyperkeratosis, sometimes with extension to the dorsum, is a further differentiating feature from NS.</p><p></p><p class="headingAnchor" id="H2385439367"><span class="h1">MANAGEMENT</span><span class="headingEndMark"> — </span>There is no specific therapy for NS. Neonates with erythroderma need in-hospital treatment and monitoring due to the potential for severe failure to thrive, metabolic abnormalities, and sepsis. In older children and adults, treatment is largely symptomatic and should be tailored to the needs of the individual patient.</p><p class="headingAnchor" id="H3646986566"><span class="h2">Neonates</span><span class="headingEndMark"> — </span>The erythrodermic neonate with NS should be managed in a neonatal intensive care unit. The initial management involves:</p><p class="bulletIndent1"><span class="glyph">●</span>Monitoring of fluids and electrolytes – Due to transepidermal water loss, neonates with NS are at risk of hypernatremic dehydration. (See  <a class="medical medical_review" href="/z/d/html/5065.html" rel="external">"Fluid and electrolyte therapy in newborns"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Monitoring of body temperature – The transepidermal water loss is always accompanied by heat loss, resulting in hypothermia and increased metabolic rate.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Prevention and treatment of infection, particularly skin infection from <em>Staphylococcus aureus</em>, <em>Streptococcus</em>, or gram-negative bacteria.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Providing adequate nutrition – Failure to thrive is common, due to increased metabolic rate and significant protein loss from skin desquamation. Early institution of a hypoallergenic diet is often considered. For some infants with severe failure to thrive and poor nutritional uptake, gastrointestinal tube (G-tube) supplemental feedings may be necessary.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Skin care – Regular bathing and liberal application of petrolatum-based ointment multiple times per day may be helpful in restoring the skin barrier function. Awareness of the risk for transcutaneous absorption and avoidance of topical medicaments (eg, topical corticosteroids) that could be absorbed transcutaneously is important.</p><p></p><p class="headingAnchor" id="H1365174391"><span class="h2">Infants and older children</span></p><p class="headingAnchor" id="H111404878"><span class="h3">General measures</span><span class="headingEndMark"> — </span>Patients with NS exhibit a variable severity of the skin involvement, and some improve over time. Careful skin care is a central part of management and involves the use of minimal amounts of mild cleansers combined with liberal, frequent use of bland emollients.</p><p>Oral antihistamines may be helpful in controlling pruritus. Topical or systemic antibiotics may be needed for the treatment of bacterial skin superinfection.</p><p>Inflammatory skin lesions may respond to topical and systemic anti-inflammatory therapies. Several reports have noted benefit to patients from narrowband ultraviolet B phototherapy [<a href="#rid42">42-44</a>].</p><p class="headingAnchor" id="H1201903989"><span class="h3">Topical therapies</span><span class="headingEndMark"> — </span>The use of low-potency corticosteroids as well as topical calcineurin inhibitors has been of benefit in some cases of NS. However, increased absorption of these agents due to the severe skin barrier dysfunction has been documented in several patients:</p><p class="bulletIndent1"><span class="glyph">●</span>Cushing syndrome from percutaneous absorption of a low-potency topical corticosteroid has been reported in a single patient with NS [<a href="#rid45">45</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a small series of three children with NS treated with <a class="drug drug_general" data-topicid="10162" href="/z/d/drug information/10162.html" rel="external">pimecrolimus</a> 1% cream twice daily for 18 months, pimecrolimus was detected in the blood of all patients, with levels ranging from 0.625 to 7.08 ng/mL [<a href="#rid46">46</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In another study of three children with severe skin involvement treated with <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> 0.1% ointment twice daily for up to eight months, significant systemic absorption 2 to 30 hours after application was documented in all, ranging from 10 to 37 ng/mL (therapeutic trough range in organ transplant recipients 5 to 20 ng/mL) [<a href="#rid47">47</a>].</p><p></p><p>Based upon these observations, topical corticosteroids and topical calcineurin inhibitors should be used with great caution and for limited periods of time in patients with NS who have extensive skin involvement. In particular, topical <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> is associated with a high risk of systemic toxicity in these patients.</p><p class="headingAnchor" id="H2071076945"><span class="h3">Systemic therapies</span><span class="headingEndMark"> — </span>Intravenous immunoglobulin (<a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">IVIG</a>) replacement therapy has led to improvement in some patients with severe NS, emphasizing the role of immune and inflammatory dysregulation in the symptoms of the disease. In one study, five children aged six months to nine years with NS and recurrent skin and pulmonary infections from <em>S. aureus</em> were treated with IVIG (0.4 g/kg/month) for one year [<a href="#rid48">48</a>]. For all patients, families reported improvement of inflammation and itching of the skin, infection, and hair fragility.</p><p>There are isolated reports of successful use of tumor necrosis factor (TNF)-alpha inhibitors (eg, <a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">infliximab</a>) and the humanized monoclonal antibody against interleukin (IL) 17A <a class="drug drug_general" data-topicid="107448" href="/z/d/drug information/107448.html" rel="external">ixekizumab</a> for the treatment of the inflammatory skin lesions in NS [<a href="#rid49">49,50</a>].</p><p class="headingAnchor" id="H1861464094"><span class="h3">Experimental therapies</span><span class="headingEndMark"> — </span>Kallikrein inhibitors are under investigation and development and appear to ameliorate symptoms of NS in animal models [<a href="#rid51">51</a>]. Gene therapy using a lentiviral vector encoding the serine protease inhibitor of Kazal type 5 (<em>SPINK5</em>) gene is also under investigation [<a href="#rid52">52,53</a>].</p><p class="headingAnchor" id="H3442240574"><span class="h2">Surveillance</span><span class="headingEndMark"> — </span>Adults with NS may develop cutaneous squamous cell carcinomas and basal cell carcinomas at an early age. Routine skin examination, once a year until first skin cancer and then more often as needed, is recommended. Providers should have a low threshold for biopsying suspicious lesions to rule out malignancy [<a href="#rid5">5</a>].</p><p class="headingAnchor" id="H1074387637"><span class="h1">GENETIC COUNSELING</span><span class="headingEndMark"> — </span>Parents of a patient with NS are obligate heterozygotes. They are typically asymptomatic and carry one of the mutations in the serine protease inhibitor of Kazal type 5 gene (<em>SPINK5</em>).</p><p>At conception, each sibling of an NS patient has a 25 percent chance of being affected, a 50 percent chance of being an asymptomatic carrier, and a 25 percent chance of being homozygous wild type and thus not affected and not a carrier. Once born and known to be unaffected, the sibling's risk changes to having a two-thirds chance of being an asymptomatic carrier. Prenatal diagnosis is possible [<a href="#rid37">37,54</a>].</p><p>Children of a patient with NS are obligate heterozygotes. In the rare chance that a reproductive partner is a carrier of a <em>SPINK5</em> mutation, the offspring have a 50 percent risk of being affected with NS and 50 percent risk of being carriers.</p><p>Each sibling of a proband's parents has a 50 percent risk of being a carrier. Carrier testing is possible once both pathogenic <em>SPINK5</em> mutations are known.</p><p class="headingAnchor" id="H4046463443"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>The erythrodermic newborn with NS has a very high risk of potentially life-threatening complications, such as hypernatremic dehydration, sepsis, and hypothermia. The reported mortality rate is approximately 20 percent in the first year of life [<a href="#rid3">3</a>].</p><p>The prognosis is favorable for patients with NS who evolve to a milder phenotype over time. Multiple cutaneous squamous cell carcinomas and basal cell carcinomas may develop at an early age [<a href="#rid24">24</a>].</p><p class="headingAnchor" id="H3791076825"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition</strong> – Netherton syndrome (NS) is a rare autosomal recessive disorder of cornification presenting with inflammatory and scaly skin lesions along with characteristic hair abnormalities and an increased incidence of allergic disease.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathogenesis</strong> – NS is caused by germline mutations in the serine protease inhibitor of Kazal type 5 (<em>SPINK5</em>) gene, which encodes a serine protein kinase known as lymphoepithelial Kazal type inhibitor (LEKTI). (See <a class="local">'Pathogenesis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical presentation</strong> – The phenotype of NS is variable. Newborns typically present with severe scaly erythroderma and a high risk of life-threatening complications, including hypernatremic dehydration, hypothermia, and sepsis (see <a class="local">'Neonatal findings'</a> above). With age, most patients evolve to a milder cutaneous phenotype, with erythematous patches and scaling mimicking an eczematous eruption such as atopic dermatitis. Eventually, many develop the characteristic ichthyosis linearis circumflexa  (<a class="graphic graphic_picture graphicRef87482" href="/z/d/graphic/87482.html" rel="external">picture 2</a>). Hair findings include the trichorrhexis nodosa and the pathognomonic trichorrhexis invaginata. (See <a class="local">'Cutaneous manifestations'</a> above and <a class="local">'Hair abnormalities'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Atopic manifestations</strong> – Most patients with NS have elevated immunoglobulin E (IgE) levels and eosinophilia. Manifestations of atopy include atopic dermatitis, food allergies, hay fever, and anaphylaxis. (See <a class="local">'Atopic manifestations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – The diagnosis of NS is based upon one or more of the following findings in addition to allergic disease (ie, atopic dermatitis, atopic diathesis, food allergies, hay fever, history of anaphylaxis, elevated IgE levels):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Typical hair findings (eg, trichorrhexis invaginata, "golf-tee" and "matchstick" hairs)</p><p class="bulletIndent2"><span class="glyph">•</span>History of NS in a sibling</p><p class="bulletIndent2"><span class="glyph">•</span>Identification of a germline <em>SPINK5</em> mutation by DNA sequencing (see <a class="local">'Diagnosis'</a> above)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong> – The treatment of NS is largely symptomatic and involves primarily a gentle skin care with mild detergents and liberal and frequent use of bland emollients. Inflammatory skin lesions may benefit from topical corticosteroids or topical calcineurin inhibitors. However, due to the elevated risk of systemic absorption, topical medications should be used with great caution in these patients. Intravenous immune globulins have been reported as beneficial in a few patients. (See <a class="local">'Management'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">NETHERTON EW. A unique case of trichorrhexis nodosa; bamboo hairs. AMA Arch Derm 1958; 78:483.</a></li><li><a class="nounderline abstract_t">Sun JD, Linden KG. Netherton syndrome: a case report and review of the literature. Int J Dermatol 2006; 45:693.</a></li><li><a class="nounderline abstract_t">Pruszkowski A, Bodemer C, Fraitag S, et al. Neonatal and infantile erythrodermas: a retrospective study of 51 patients. Arch Dermatol 2000; 136:875.</a></li><li><a class="nounderline abstract_t">Chavanas S, Bodemer C, Rochat A, et al. Mutations in SPINK5, encoding a serine protease inhibitor, cause Netherton syndrome. Nat Genet 2000; 25:141.</a></li><li><a class="nounderline abstract_t">Hovnanian A. Netherton syndrome: skin inflammation and allergy by loss of protease inhibition. Cell Tissue Res 2013; 351:289.</a></li><li><a class="nounderline abstract_t">Fortugno P, Furio L, Teson M, et al. The 420K LEKTI variant alters LEKTI proteolytic activation and results in protease deregulation: implications for atopic dermatitis. Hum Mol Genet 2012; 21:4187.</a></li><li><a class="nounderline abstract_t">Kato A, Fukai K, Oiso N, et al. Association of SPINK5 gene polymorphisms with atopic dermatitis in the Japanese population. Br J Dermatol 2003; 148:665.</a></li><li><a class="nounderline abstract_t">Walley AJ, Chavanas S, Moffatt MF, et al. Gene polymorphism in Netherton and common atopic disease. Nat Genet 2001; 29:175.</a></li><li><a class="nounderline abstract_t">Furio L, Hovnanian A. Netherton syndrome: defective kallikrein inhibition in the skin leads to skin inflammation and allergy. Biol Chem 2014; 395:945.</a></li><li><a class="nounderline abstract_t">Furio L, Pampalakis G, Michael IP, et al. KLK5 Inactivation Reverses Cutaneous Hallmarks of Netherton Syndrome. PLoS Genet 2015; 11:e1005389.</a></li><li><a class="nounderline abstract_t">Chan A, Godoy-Gijon E, Nuno-Gonzalez A, et al. Cellular basis of secondary infections and impaired desquamation in certain inherited ichthyoses. JAMA Dermatol 2015; 151:285.</a></li><li><a class="nounderline abstract_t">Paller AS, Renert-Yuval Y, Suprun M, et al. An IL-17-dominant immune profile is shared across the major orphan forms of ichthyosis. J Allergy Clin Immunol 2017; 139:152.</a></li><li><a class="nounderline abstract_t">Hachem JP, Wagberg F, Schmuth M, et al. Serine protease activity and residual LEKTI expression determine phenotype in Netherton syndrome. J Invest Dermatol 2006; 126:1609.</a></li><li><a class="nounderline abstract_t">Komatsu N, Saijoh K, Jayakumar A, et al. Correlation between SPINK5 gene mutations and clinical manifestations in Netherton syndrome patients. J Invest Dermatol 2008; 128:1148.</a></li><li><a class="nounderline abstract_t">Itoh K, Kako T, Suzuki N, et al. Severe lethal phenotype of a Japanese case of Netherton syndrome with homozygous founder mutations of SPINK5 c.375_376delAT. J Dermatol 2015; 42:1212.</a></li><li><a class="nounderline abstract_t">Diociaiuti A, Castiglia D, Fortugno P, et al. Lethal Netherton syndrome due to homozygous p.Arg371X mutation in SPINK5. Pediatr Dermatol 2013; 30:e65.</a></li><li><a class="nounderline abstract_t">Capri Y, Vanlieferinghen P, Boeuf B, et al. [A lethal variant of Netherton syndrome in a large inbred family]. Arch Pediatr 2011; 18:294.</a></li><li><a class="nounderline abstract_t">Small AM, Cordoro KM. Netherton Syndrome Mimicking Pustular Psoriasis: Clinical Implications and Response to Intravenous Immunoglobulin. Pediatr Dermatol 2016; 33:e222.</a></li><li><a class="nounderline abstract_t">Mendiratta V, Yadav P, Chander R, Aggarwal S. Recurrent pustular eruption masquerading as pustular psoriasis in Netherton syndrome. Pediatr Dermatol 2015; 32:147.</a></li><li><a class="nounderline abstract_t">Guerra L, Fortugno P, Pedicelli C, et al. Ichthyosis Linearis Circumflexa as the Only Clinical Manifestation of Netherton Syndrome. Acta Derm Venereol 2015; 95:720.</a></li><li><a class="nounderline abstract_t">Guerra L, Fortugno P, Sinistro A, et al. Betapapillomavirus in multiple non-melanoma skin cancers of Netherton syndrome: Case report and published work review. J Dermatol 2015; 42:786.</a></li><li><a class="nounderline abstract_t">Ashton R, Moledina J, Sivakumar B, et al. Considerations in surgical management of a Buschke-Lowenstein tumor in Netherton syndrome: A case report. Pediatr Dermatol 2017; 34:e328.</a></li><li><a class="nounderline abstract_t">Li AL, Walsh S, McKay DR. Surgical management of a giant condyloma of Buschke-Löwenstein in a patient with Netherton syndrome using the pedicled anterolateral thigh flap--a case report. J Plast Reconstr Aesthet Surg 2011; 64:1533.</a></li><li><a class="nounderline abstract_t">Natsuga K, Akiyama M, Shimizu H. Malignant skin tumours in patients with inherited ichthyosis. Br J Dermatol 2011; 165:263.</a></li><li><a class="nounderline abstract_t">van der Voort EA, Prens EP. Netherton syndrome with multiple non-melanoma skin cancers. Acta Derm Venereol 2013; 93:727.</a></li><li><a class="nounderline abstract_t">Torchia D, Schachner LA. Picture of the month. Comèl-Netherton syndrome without bamboo hair. Arch Pediatr Adolesc Med 2011; 165:763.</a></li><li><a class="nounderline abstract_t">Hannula-Jouppi K, Laasanen SL, Heikkilä H, et al. IgE allergen component-based profiling and atopic manifestations in patients with Netherton syndrome. J Allergy Clin Immunol 2014; 134:985.</a></li><li><a class="nounderline abstract_t">Aydın BK, Baş F, Tamay Z, et al. Netherton syndrome associated with growth hormone deficiency. Pediatr Dermatol 2014; 31:90.</a></li><li><a class="nounderline abstract_t">Machet P, Bodemer C, Lorette G, et al. Exocrine pancreatic insufficiency in a child with Netherton syndrome. Eur J Dermatol 2016; 26:311.</a></li><li><a class="nounderline abstract_t">Leclerc-Mercier S, Bodemer C, Furio L, et al. Skin Biopsy in Netherton Syndrome: A Histological Review of a Large Series and New Findings. Am J Dermatopathol 2016; 38:83.</a></li><li><a class="nounderline abstract_t">Rakowska A, Kowalska-Oledzka E, Slowinska M, et al. Hair shaft videodermoscopy in netherton syndrome. Pediatr Dermatol 2009; 26:320.</a></li><li><a class="nounderline abstract_t">Bittencourt Mde J, Moure ER, Pies OT, et al. Trichoscopy as a diagnostic tool in trichorrhexis invaginata and Netherton syndrome. An Bras Dermatol 2015; 90:114.</a></li><li><a class="nounderline abstract_t">de Berker DA, Paige DG, Ferguson DJ, Dawber RP. Golf tee hairs in Netherton disease. Pediatr Dermatol 1995; 12:7.</a></li><li><a class="nounderline abstract_t">Sárdy M, Fáy A, Kárpáti S, Horváth A. Comèl-Netherton syndrome and peeling skin syndrome type B: overlapping syndromes or one entity? Int J Dermatol 2002; 41:264.</a></li><li><a class="nounderline abstract_t">Powell J, Dawber RP, Ferguson DJ, Griffiths WA. Netherton's syndrome: increased likelihood of diagnosis by examining eyebrow hairs. Br J Dermatol 1999; 141:544.</a></li><li><a class="nounderline abstract_t">Goujon E, Beer F, Fraitag S, et al. 'Matchstick' eyebrow hairs: a dermoscopic clue to the diagnosis of Netherton syndrome. J Eur Acad Dermatol Venereol 2010; 24:740.</a></li><li><a class="nounderline abstract_t">Sprecher E, Chavanas S, DiGiovanna JJ, et al. The spectrum of pathogenic mutations in SPINK5 in 19 families with Netherton syndrome: implications for mutation detection and first case of prenatal diagnosis. J Invest Dermatol 2001; 117:179.</a></li><li><a class="nounderline abstract_t">Farooq M, Kurban M, Abbas O, et al. Netherton syndrome showing a large clinical overlap with generalized inflammatory peeling skin syndrome. Eur J Dermatol 2012; 22:412.</a></li><li><a class="nounderline abstract_t">Hernández-Martín A, González-Sarmiento R. Recent advances in congenital ichthyoses. Curr Opin Pediatr 2015; 27:473.</a></li><li><a class="nounderline abstract_t">Samuelov L, Sprecher E. Peeling off the genetics of atopic dermatitis-like congenital disorders. J Allergy Clin Immunol 2014; 134:808.</a></li><li><a class="nounderline abstract_t">Moosbrugger-Martinz V, Jalili A, Schossig AS, et al. Epidermal barrier abnormalities in exfoliative ichthyosis with a novel homozygous loss-of-function mutation in CSTA. Br J Dermatol 2015; 172:1628.</a></li><li><a class="nounderline abstract_t">Kaminska EC, Ortel B, Sharma V, Stein SL. Narrowband UVB phototherapy as a novel treatment for Netherton syndrome. Photodermatol Photoimmunol Photomed 2012; 28:162.</a></li><li><a class="nounderline abstract_t">Maatouk I, Moutran R, Tomb R. Narrowband ultraviolet B phototherapy associated with improvement in Netherton syndrome. Clin Exp Dermatol 2012; 37:364.</a></li><li><a class="nounderline abstract_t">Singer R, Çopur M, Yüksel EN, et al. Ichthyosis linearis circumflexa in a child. Response to narrowband UVB therapy. J Dermatol Case Rep 2015; 9:110.</a></li><li><a class="nounderline abstract_t">Halverstam CP, Vachharajani A, Mallory SB. Cushing syndrome from percutaneous absorption of 1% hydrocortisone ointment in Netherton syndrome. Pediatr Dermatol 2007; 24:42.</a></li><li><a class="nounderline abstract_t">Yan AC, Honig PJ, Ming ME, et al. The safety and efficacy of pimecrolimus, 1%, cream for the treatment of Netherton syndrome: results from an exploratory study. Arch Dermatol 2010; 146:57.</a></li><li><a class="nounderline abstract_t">Allen A, Siegfried E, Silverman R, et al. Significant absorption of topical tacrolimus in 3 patients with Netherton syndrome. Arch Dermatol 2001; 137:747.</a></li><li><a class="nounderline abstract_t">Renner ED, Hartl D, Rylaarsdam S, et al. Comèl-Netherton syndrome defined as primary immunodeficiency. J Allergy Clin Immunol 2009; 124:536.</a></li><li><a class="nounderline abstract_t">Fontao L, Laffitte E, Briot A, et al. Infliximab infusions for Netherton syndrome: sustained clinical improvement correlates with a reduction of thymic stromal lymphopoietin levels in the skin. J Invest Dermatol 2011; 131:1947.</a></li><li><a class="nounderline abstract_t">Barbieux C, Bonnet des Claustres M, de la Brassinne M, et al. Duality of Netherton syndrome manifestations and response to ixekizumab. J Am Acad Dermatol 2021; 84:1476.</a></li><li><a class="nounderline abstract_t">Tan X, Soualmia F, Furio L, et al. Toward the first class of suicide inhibitors of kallikreins involved in skin diseases. J Med Chem 2015; 58:598.</a></li><li><a class="nounderline abstract_t">Di WL, Mellerio JE, Bernadis C, et al. Phase I study protocol for ex vivo lentiviral gene therapy for the inherited skin disease, Netherton syndrome. Hum Gene Ther Clin Dev 2013; 24:182.</a></li><li><a class="nounderline abstract_t">Di WL, Lwin SM, Petrova A, et al. Generation and Clinical Application of Gene-Modified Autologous Epidermal Sheets in Netherton Syndrome: Lessons Learned from a Phase 1 Trial. Hum Gene Ther 2019; 30:1067.</a></li><li><a class="nounderline abstract_t">Bitoun E, Bodemer C, Amiel J, et al. Prenatal diagnosis of a lethal form of Netherton syndrome by SPINK5 mutation analysis. Prenat Diagn 2002; 22:121.</a></li></ol></div><div id="topicVersionRevision">Topic 15474 Version 7.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13582191" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : A unique case of trichorrhexis nodosa; bamboo hairs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16796630" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Netherton syndrome: a case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10890989" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Neonatal and infantile erythrodermas: a retrospective study of 51 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10835624" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Mutations in SPINK5, encoding a serine protease inhibitor, cause Netherton syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23344365" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Netherton syndrome: skin inflammation and allergy by loss of protease inhibition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22730493" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : The 420K LEKTI variant alters LEKTI proteolytic activation and results in protease deregulation: implications for atopic dermatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12752122" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Association of SPINK5 gene polymorphisms with atopic dermatitis in the Japanese population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11544479" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Gene polymorphism in Netherton and common atopic disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25153381" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Netherton syndrome: defective kallikrein inhibition in the skin leads to skin inflammation and allergy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26390218" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : KLK5 Inactivation Reverses Cutaneous Hallmarks of Netherton Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25565224" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Cellular basis of secondary infections and impaired desquamation in certain inherited ichthyoses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27554821" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : An IL-17-dominant immune profile is shared across the major orphan forms of ichthyosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16601670" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Serine protease activity and residual LEKTI expression determine phenotype in Netherton syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17989726" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Correlation between SPINK5 gene mutations and clinical manifestations in Netherton syndrome patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26365906" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Severe lethal phenotype of a Japanese case of Netherton syndrome with homozygous founder mutations of SPINK5 c.375_376delAT.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23331056" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Lethal Netherton syndrome due to homozygous p.Arg371X mutation in SPINK5.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21255986" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : [A lethal variant of Netherton syndrome in a large inbred family].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27086664" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Netherton Syndrome Mimicking Pustular Psoriasis: Clinical Implications and Response to Intravenous Immunoglobulin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25440527" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Recurrent pustular eruption masquerading as pustular psoriasis in Netherton syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25710899" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Ichthyosis Linearis Circumflexa as the Only Clinical Manifestation of Netherton Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25917539" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Betapapillomavirus in multiple non-melanoma skin cancers of Netherton syndrome: Case report and published work review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29144034" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Considerations in surgical management of a Buschke-Lowenstein tumor in Netherton syndrome: A case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21463975" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Surgical management of a giant condyloma of Buschke-Löwenstein in a patient with Netherton syndrome using the pedicled anterolateral thigh flap--a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21517795" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Malignant skin tumours in patients with inherited ichthyosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23571873" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Netherton syndrome with multiple non-melanoma skin cancers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21810639" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Picture of the month. Comèl-Netherton syndrome without bamboo hair.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25159469" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : IgE allergen component-based profiling and atopic manifestations in patients with Netherton syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24015757" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Netherton syndrome associated with growth hormone deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26986028" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Exocrine pancreatic insufficiency in a child with Netherton syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26825155" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Skin Biopsy in Netherton Syndrome: A Histological Review of a Large Series and New Findings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19706096" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Hair shaft videodermoscopy in netherton syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25672309" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Trichoscopy as a diagnostic tool in trichorrhexis invaginata and Netherton syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7792228" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Golf tee hairs in Netherton disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12100700" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Comèl-Netherton syndrome and peeling skin syndrome type B: overlapping syndromes or one entity?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10583065" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Netherton's syndrome: increased likelihood of diagnosis by examining eyebrow hairs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19840201" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : 'Matchstick' eyebrow hairs: a dermoscopic clue to the diagnosis of Netherton syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11511292" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : The spectrum of pathogenic mutations in SPINK5 in 19 families with Netherton syndrome: implications for mutation detection and first case of prenatal diagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22562784" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Netherton syndrome showing a large clinical overlap with generalized inflammatory peeling skin syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26164154" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Recent advances in congenital ichthyoses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25282561" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Peeling off the genetics of atopic dermatitis-like congenital disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25400170" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Epidermal barrier abnormalities in exfoliative ichthyosis with a novel homozygous loss-of-function mutation in CSTA.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22548400" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Narrowband UVB phototherapy as a novel treatment for Netherton syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22582910" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Narrowband ultraviolet B phototherapy associated with improvement in Netherton syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26848320" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Ichthyosis linearis circumflexa in a child. Response to narrowband UVB therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17300648" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Cushing syndrome from percutaneous absorption of 1% hydrocortisone ointment in Netherton syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20083693" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : The safety and efficacy of pimecrolimus, 1%, cream for the treatment of Netherton syndrome: results from an exploratory study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11405764" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Significant absorption of topical tacrolimus in 3 patients with Netherton syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19683336" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Comèl-Netherton syndrome defined as primary immunodeficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21654837" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Infliximab infusions for Netherton syndrome: sustained clinical improvement correlates with a reduction of thymic stromal lymphopoietin levels in the skin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32692997" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Duality of Netherton syndrome manifestations and response to ixekizumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25489658" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Toward the first class of suicide inhibitors of kallikreins involved in skin diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24329107" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Phase I study protocol for ex vivo lentiviral gene therapy for the inherited skin disease, Netherton syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31288584" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Generation and Clinical Application of Gene-Modified Autologous Epidermal Sheets in Netherton Syndrome: Lessons Learned from a Phase 1 Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11857617" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Prenatal diagnosis of a lethal form of Netherton syndrome by SPINK5 mutation analysis.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
